March 17, 2020

Letter to the Coalition for Hemophilia B

As the Coronavirus outbreak continues to expand across the globe, CSL Behring is actively monitoring the potential impact on our products and patients. CSL will implement any precautionary measures necessary to safeguard our ability to deliver our life-saving medicines to patients who rely on them.

At this time, we are not experiencing any issues with product supply, and our robust supply chain ensures that critical materials are not single sourced.

Throughout this difficult time, CSL Behring remains committed to the hemophilia community and will provide updates as appropriate and keep you informed as the global and national situation continues to evolve.